Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.

A Two-part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single and Repeat Doses of Intravenously Infused GSK1995057 in Healthy Subjects.

The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing. The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the body and excreted, and what some of the effects of the study drug are.

Study Overview

• Status: Completed
• Conditions: Respiratory Disorders
• Intervention / Treatment: Drug: GSK1995057 single dose; Drug: Placebo

Detailed Description

This study will be the first investigation of GSK1995057 in humans and is primarily designed to investigate safety and tolerability of single and repeat intravenously infused doses. The study will enrol healthy male subjects and healthy female subjects of non-child bearing potential and will also investigate immunogenicity, GSK1995057 distribution (pharmacokinetics), and potential impact on indicators of host immunity and normal immunological function. Safety, tolerability, immunogenicity, pharmacokinetic and pharmacodynamic data from this trial may facilitate further clinical investigations in healthy subjects dosed with GSK1995057 via the inhaled route, and ultimately clinical trials in patients with acute lung injury.

• Study Type: Interventional
• Enrollment (Actual): 56
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Middlesex
    • Harrow, Middlesex, United Kingdom
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy as determined by a responsible and experienced physician.
• Male or female between 18 and 55 years of age inclusive
• A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea and elevated FSH as per the local laboratory guidelines.
• Normal creatinine clearance values at screening
• Male subjects must agree to use one of the study specific contraception methods
• Body weight ≥ 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive).
• Normal lung function at screening.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Available to complete all study assessments.
• Able to read, comprehend and write English at a sufficient level to complete study elated materials.

Exclusion Criteria:

• A history of Hepatitis B, Hepatitis C or HIV infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities. (With the exception of known Gilbert's syndrome or asymptomatic gallstones).
• A positive pre-study drug/alcohol screen.
• Evidence of previous or active mycobacterium tuberculosis complex infection
• Recent history of and/or a positive test for Toxoplasma consistent with active oxoplasmosis infection.
• A positive test for influenza A/B taken within 7 days before dosing.
• Current evidence or history of an influenza-like illness.
• Corrected QT interval (QTcF) >450msec from ECG readings.
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol and the following can be used as a guide: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
• The subject is unwilling to abstain from alcohol consumption from 24 hr prior to dosing until discharge from the clinic, and for 24 hr prior to all other out-patient clinic visits.
• Subjects with a smoking history of >10 cigarettes per day in the last 3 months.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) or exposure to more than four new chemical or biological entities within 12 months prior to the first dosing day.
• Subjects having received any type of vaccination within 3 weeks of the anticipated dosing start or are expected to be vaccinated within 3 weeks after the last dose.
• Current evidence of ongoing or acute infection, history of repeated or chronic significant infections or history of serious infection within three months of dosing.
• Subjects who have asthma or a history of asthma, COPD, other respiratory conditions or recurrent infections (a subject who suffered from childhood asthma but not as an adult may be included provided they fulfil other entry criteria).
• Subjects who have a known history of migraine headaches or are frequently suffering from other types of headaches which require medication (frequent defined as more than one headache in a fortnight).
• Use of prescription or non-prescription drugs (except simple analgesics), including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsors Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including severe allergic reaction, angio-edema or anaphylaxis that, in the opinion of the investigator or sponsors Medical Monitor, contraindicates their participation.
• History of malignancy, except for adequately treated non-invasive cancer of the skin (basal or squamous cell) or cervical carcinoma in situ (>2 yrs prior to dosing).
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 3 month or 90 day period.
• Subject is unable to refrain from travelling to countries with a high prevalence of TB or other areas of prevalent infectious disease as judged by the investigator or the sponsors medical monitor from the start of screening until the final follow-up visit.
• Subject is mentally or legally incapacitated.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Single intravenous dose	Drug: Placebo; Single intravenous dose
Experimental: GSK1995057; Single intravenous dose	Drug: GSK1995057 single dose; Single intravenous dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurance of adverse events.	Number and type of adverse events recorded during study.	From start of screening until 84 days after completion of single dose (Part A subjects) or first dose (Part B subjects).
Change from baseline in blood pressure.	Systolic and diastolic blood pressure values before and after dosing completion.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in heart rate.	Heart rate before and after dosing completion.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in respiration rate.	Respiration rate before and after dosing completion.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in body temperature.	Body temperature before and after dosing completion.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in heart function.	Holter recording.	For 24hrs during screening, then for 1 hour before dosing to 24 hours after dosing starts (in Part A subjects only, except for cohort 7).
Change from baseline in heart function	Lead II cardiac telemetry.	From 1 hour before dosing to 12 hours after dosing starts for each dose.
Change from baseline in heart function.	12-lead ECG recording.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in lung function.	FEV1 and FVC measurements.	From start of screening until 28 days after completion of single or repeat dosing.
Change from baseline in laboratory safety data.	Clinical chemistry, haematology and routine urinalysis.	From start of screening until 28 days after completion of single or repeat dosing.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma pharmacokinetics of GSK1995057	Levels of GSK1995057 in blood samples.	From the first day of dosing until 48 hours after the completion of dosing.
Urine pharmacokinetics of GSK1995057	Levels of GSK1995057 in urine samples from cohort 6 subjects only.	From 1 hour before the only dose until 48 hours after the dose.
Bronchoalveolar lavage fluid (BALF) (saline flushed into and then collected from a lung) pharmacokinetics.	Levels of GSK1995057 in BALF from cohort 7 subjects only.	At 2 hrs after the completion of the only dose.
Effect of GSK1995057 on host immunity and immunological function	Levels of pharmacodynamic and immune function biomarkers in blood samples.	From the day before dosing starts to 28 days after dosing completion.
Effects of GSK1995057 on host immunity and immunological function	Levels of pharmacodynamic and immune function biomarkers in BALF from cohort 7 subjects only.	At 2 hrs after the completion of the only dose.
Immunogenic effect of GSK1995057	Levels of anti-GSK1995057 antibodies in blood samples	From the start of screening (cohorts 1-4 only) or from the day before the start of dosing until 84 days after the completion of single or repeat dosing.

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2011
• Primary Completion (Actual): June 17, 2012
• Study Completion (Actual): June 17, 2012

Study Registration Dates

• First Submitted: March 15, 2011
• First Submitted That Met QC Criteria: November 17, 2011
• First Posted (Estimate): November 22, 2011

Study Record Updates

• Last Update Posted (Actual): June 12, 2017
• Last Update Submitted That Met QC Criteria: June 9, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
• Additional Relevant MeSH Terms: Respiration Disorders; Respiratory Tract Diseases
• Other Study ID Numbers: 110951

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Dataset Specification
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Study Protocol
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Informed Consent Form
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Individual Participant Data Set
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Annotated Case Report Form
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Statistical Analysis Plan
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Clinical Study Report
   Information identifier: 110951
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register